|
Harbin Jixianglong Biotech Co., Ltd.
|
Terlipressin Acetate:
CAS No. : 14636-12-5
Peptide Sequence:
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2(Disulfide bridge: Cys4-Cys9)
Terlipressin acetate is a vasopressin analog with potent vasoactive properties, which can reduce visceral blood flow and portal pressure and control acute varicose rupture bleeding. Terlipressin acetate can be used to treat hepatorenal syndrome as well.
| Product Name |
Terlipressin Acetate |
| CAS NO. |
14636-12-5 |
| Appearance |
White Powder |
| Purity |
>99% or customized |
| Application |
Drug peptides |
| Usage |
Terlipressin acetate can reduce visceral blood flow and portal pressure and control acute varicose rupture bleeding, used to treat hepatorenal syndrome as well. |
Related Products
| Name |
CAS No. |
Name |
CAS No. |
| Eptifibatide |
188627-80-7 |
Thymalfasin |
69440-99-9 |
| Terlipressin Acetate |
14636-12-5 |
Thymopentin Acetate (TP-5) |
69558-55-0 |
| Astosiban Acetate |
90779-69-4 |
Octreotide Acetate |
83150-76-9 |
| Liraglutide |
204656-20-2 |
Melanotan II Acetate |
121062-08-6 |
| Teriparatide |
52232-67-4 |
Melanotan I Acetate |
75921-69-6 |
| Bivalirudin |
128270-60-0 |
Secretin Acetate |
17034-35-4 |
| Carbetocin |
37025-55-1 |
Ornipressin Acetate |
3397-23-7 |
| Thymosin Beta 4 |
77591-33-4 |
Oxytocin Acetate |
50-56-6 |
| Calcitonin |
60731-46-6 |
Lypressin Acetate |
50-57-7 |
| Semaglutide |
910463-68-2 |
Argpressin Acetate |
113-79-1 |
| Abaloparatide |
247062-33-5 |
Calcitonin (Salmone) Acetate |
47931-85-1 |
  Company Profile
Founded in 2011, Harbin Jixianglong Biotech Co., Ltd. is a is a professional high-tech company specializing in R&D and production of polypeptide pharmaceuticals. Our advanced industry chain occupied in R&D, approbation and industrialization of peptides API and preparation.
Jixianglong has peptide drug production workshop and pilot workshop for personalized cancer neoantigen peptide vaccine which approved by GMP standard. More than 300 sets advanced instruments for production and testing, such as Solid phase synthesizer, Preparative liquid chromatograph, Freeze dryer, High performance liquid chromatograph etc.
Main Products:
10 items completed polypeptide API declared:
Eptifibatide, Somatostatin, Terlipressin Acetate, Thymalfasin, Atosiban Acetate, Carbetocin, Oxytocin, Ganirelix Acetate, Octreotide Acetate, Cetrorelix Acetate.
N items as researching reserve series:
Teriparatide, Bivalirudin, Liraglutide, Nesiritide, Abaloparatide, Semaglutide, Personalized cancer neoantigen peptide vaccine, Peptide drug conjugate (PDC).
 
|
Send Inquiry
|
|
ZHEJIANG SACHEM PHARMACEUTICAL TECHNOLOGY CO.,LTD.
|
Since its establishment, Zhejiang Saikai Pharmaceutical Technology Co., Ltd. has continuously enhanced its resource integration ability around the pharmaceutical industry chain, built an enterprise-oriented and market-oriented business system, actively identified the key links of the upstream and downstream of the industrial chain, and promoted the overall improvement of the supply chain.
The company has always been committed to opening the international market for small and medium-sized production enterprises. Through the efforts of professional international business team, the company has helped steroid hormone apis and intermediates gain a certain market voice in India. Based on the existing achievements, the company insists on expanding the product line, and has established cooperative relations with many manufacturers in Zhejiang, Hunan, Jiangsu and other provinces. In addition to India, the products are exported to Europe, South America and other overseas regions, and a broad sales market has been established.
Since 2070, relying on the head office to carry out API import, registration and agent procurement business. Under the cooperation of the total company registration team, the company successfully completed the introduction and registration of a number of high-quality apis, and established product cooperation with foreign first-line enterprises, and successfully helped the parent company and domestic pharmaceutical customers related review.
In the future, Sikai Pharmaceutical will forge ahead, do not slack, focus on improving the level of business, to create an excellent corporate brand image. We will make full use of our own advantages, continue to integrate domestic and foreign resources, through strategic cooperation to reach a strong alliance between enterprises, to achieve mutual benefit, mutual assistance and win-win. |
Send Inquiry
|
Pharma Sources Insight June 2024: Globalization on the Go
